Rapid molecular testing in the laboratories has greatly helped oncologists to diagnose cancers of the breast, lymphoma and leukemia.
One type of cancer that is a high-profile target for improved diagnostic testing is colon cancer. It is one of the most common malignancies in men and women. The National Cancer Institute estimates that 141,210 new cases of colon and rectal cancers will be reported and an estimated 49,380 Americans will die of these diseases this year. Anytime time a lab presents new testing it requires financial,clinical and operational resources. Since there is a high rate of colon cancer it is important to have more accurate testing. Past testing such occult blood and sigmoidoscopy are variable and can have false positives. The new testing is using monoclonal and polyclonal antibodies to detect only human blood in stool, this technology has improved specificity, sensitivity, accuracy, the White Paper reported.
In conclusion, the ability of new technologies to contribute to improved performance of assays used in screening individuals for colorectal cancer demonstrate how swiftly the standard of care in laboratory medicine can be changed for the better. New generation FOB lab tests are one example of the types of changes now occurring across the entire range of testing services offered by clinical laboratories and pathology groups.